Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Bossart M, et al
Arcutis disclosed aggregated results from the Phase III INTEGUMENT-1 and INTEGUMENT-2 trials in January 2024, revealing that 91.5% of atopic dermatitis patients treated with the drug showed measurable improvement in the Eczema Area and Severity Index (EASI) score after four weeks
After reconstitution: Store the solution at 28C and use within 30 days
This review evaluates the antihypertensive potential of sodium-glucose cotransporter-2 inhibitors (SGLT2-i) and glucagon-like peptide-1 receptor agonists (GLP-1RA), particularly in patients with comorbid diabetes, HF, CKD or resistant hypertension
Glutathione and Glutamate in schizophrenia: a 7T MRS Study
US$ 29.58
US$ 29.34
US$ 24.47
US$ 23.54
